$LJPC Patent news!

On February 23, 2012, La Jolla Pharmaceutical Company (the “Company” " src="/images/icons/icon_wink.gif" alt=" " /> received from the U.S. Patent and Trademark Office a notification of issuance for the Company’s patent application covering certain claims relating to GCS-100, a galectin-3 inhibitor that is being studied for the treatment of cancer and chronic organ failure. The patent is expected to issue on or about March 6, 2012 and will expire on March 13, 2028, without giving effect to any potential patent term extensions that may be available in the future under the Hatch-Waxman Amendments to the Drug Price Competition and Patent Term Restoration Act of 1984.

http://www.otcmarkets.com/edgar/GetFilingHtml...ID=8433463